Salarsen: Biogen’s Annual ASO Shows 75% NfL Reduction in SMA Patients – Phase 3 Trials Launching This Year
By Daniel Richardson Editor-in-Chief, Archysport Boston, MA – Biogen is making significant strides in the fight against spinal muscular atrophy (SMA) with promising early results from its Phase 1b clinical trial of salanersen, a novel antisense oligonucleotide (ASO) therapy. The data, presented at the 2026 MDA Clinical & Scientific Conference, suggests salanersen could offer a … Read more